SFTPC sirna

SFTPC siRNA (Human)

Cat. Num. AAA8239398

• Gene Names: SFTPC; SP-C; PSP-C; SFTP2; SMDP2; BRICD6
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: SFTPC; SFTPC siRNA (Human); SFTP2; Pulmonary surfactant-associated protein C; SP-C; Pulmonary surfactant-associated proteolipid SPL(Val); SP5; SFTPC sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: SFTPC siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 191

• Applicable Applications for SFTPC sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human SFTPC gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for SFTPC sirna

siRNA to inhibit SFTPC expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 288915543
• NCBI GeneID: 6440
• NCBI Accession #: NP_001165828.1
• NCBI GenBank Nucleotide #: NM_001172357.1
• UniProt Accession #: P11686; P11687; Q12793; Q7Z5D0; A6XNE4; B2RE00; E9PGX3
• Molecular Weight: 20,361 Da
• NCBI Official Full Name: pulmonary surfactant-associated protein C isoform 2 proprotein
• NCBI Official Synonym Full Names: surfactant protein C
• NCBI Official Symbol: SFTPC
• NCBI Official Synonym Symbols: SP-C; PSP-C; SFTP2; SMDP2; BRICD6
• NCBI Protein Information: pulmonary surfactant-associated protein C
• UniProt Protein Name: Pulmonary surfactant-associated protein C
• Protein Family: Pulmonary surfactant-associated protein
• UniProt Gene Name: SFTPC
• UniProt Synonym Gene Names: SFTP2; SP-C
• UniProt Entry Name: PSPC_HUMAN

NCBI Description

This gene encodes the pulmonary-associated surfactant protein C (SPC), an extremely hydrophobic surfactant protein essential for lung function and homeostasis after birth. Pulmonary surfactant is a surface-active lipoprotein complex composed of 90% lipids and 10% proteins which include plasma proteins and apolipoproteins SPA, SPB, SPC and SPD. The surfactant is secreted by the alveolar cells of the lung and maintains the stability of pulmonary tissue by reducing the surface tension of fluids that coat the lung. Multiple mutations in this gene have been identified, which cause pulmonary surfactant metabolism dysfunction type 2, also called pulmonary alveolar proteinosis due to surfactant protein C deficiency, and are associated with interstitial lung disease in older infants, children, and adults. Alternatively spliced transcript variants encoding different protein isoforms have been identified.[provided by RefSeq, Feb 2010]

Uniprot Description

SFTPC: Pulmonary surfactant associated proteins promote alveolar stability by lowering the surface tension at the air- liquid interface in the peripheral air spaces. Defects in SFTPC are the cause of pulmonary surfactant metabolism dysfunction type 2 (SMDP2); also called pulmonary alveolar proteinosis due to surfactant protein C deficiency. A rare disease associated with progressive respiratory insufficiency and lung disease with a variable clinical course, due to impaired surfactant homeostasis. It is characterized by alveolar filling with floccular material that stains positive using the periodic acid-Schiff method and is derived from surfactant phospholipids and protein components. Excessive lipoproteins accumulation in the alveoli results in severe respiratory distress. Genetic variations in SFTPC are a cause of susceptibility to respiratory distress syndrome in premature infants (RDS); also known as RDS in prematurity. RDS is a lung disease affecting usually premature newborn infants. It is characterized by deficient gas exchange, diffuse atelectasis, high-permeability lung edema and fibrin-rich alveolar deposits called 'hyaline membranes'. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Lipid-binding

Chromosomal Location of Human Ortholog: 8p21

Cellular Component: multivesicular body; extracellular space

Molecular Function: protein binding; protein homodimerization activity

Biological Process: circadian rhythm; response to cAMP; response to retinoic acid; response to hyperoxia; response to glucocorticoid stimulus; response to glucose stimulus; response to lipopolysaccharide; respiratory gaseous exchange; protein homooligomerization; response to vitamin A

Disease: Pulmonary Fibrosis, Idiopathic; Surfactant Metabolism Dysfunction, Pulmonary, 2